In platelet function studies, what reagent added to PRP is likely to cause rapid and irreversible aggregation?

Adenosine diphosphate (ADP) is a potent platelet agonist that is known to induce rapid and irreversible aggregation of platelets when added to platelet-rich plasma (PRP). ADP binds to specific receptors on the surface of platelets, leading to a cascade of intracellular signaling events that enhance platelet activation and aggregation.

Upon binding of ADP to its receptors, there is a significant release of calcium ions and activation of various signaling pathways, including the activation of glycoprotein IIb/IIIa receptors, which are crucial for platelet-platelet interactions. This results in the cross-linking of platelets through fibrinogen, leading to stable and irreversible platelet aggregation.

Understanding the mechanisms of platelet aggregation is essential in clinical settings, particularly in diagnosing and managing bleeding disorders or assessing the efficacy of antiplatelet therapies in patients with cardiovascular diseases.